Morgan Stanley Procept Bio Robotics Corp Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Morgan Stanley holds 757,400 shares of PRCT stock, worth $43.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
757,400
Previous 650,773
16.38%
Holding current value
$43.6 Million
Previous $52.1 Million
16.98%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding PRCT
# of Institutions
295Shares Held
41.6MCall Options Held
196KPut Options Held
141K-
Vanguard Group Inc Valley Forge, PA5.14MShares$296 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.49MShares$201 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY1.75MShares$101 Million0.05% of portfolio
-
Wellington Management Group LLP Boston, MA1.49MShares$85.9 Million0.02% of portfolio
-
Loomis Sayles & CO L P1.21MShares$69.5 Million0.12% of portfolio
About PROCEPT BioRobotics Corp
- Ticker PRCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 44,592,300
- Market Cap $2.57B
- Description
- PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...